Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

What We Do

In Our Own Words

Our work with clients, as well as through our partnerships with envelope-pushing, multi-stakeholder efforts such as the NEWDIGS LEAPS project and the Duke-Margolis RWE Collaborative, is helping to define the future of RWE in the healthcare space.

CUP Case Study
Case Study

Robust Modeling Helped Convince NICE to Reverse Their Decision

Learn how Evidera’s experts helped to improve access to a mCRPC treatment in a country with traditionally conservative reimbursement for these therapies.

Read More
Case Study

Compassionate Use Program: Rapid Drug Delivery to Patients in Need

Learn how Evidera, as part of PPD, created a global program across 38 countries to provide treatment within 24-48 hours to 3,100 patients.

Read More

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More